(재활) 패혈증 관련 AKI 환자에서 Alkaline Phosphatase의 효능 및 안전성을 규명하기 위한 연구
SA-AKI 환자 치료를 위한 재조합 인간 알칼리 포스파타제의 효능 및 안전성을 조사하기 위한 DB, 위약 대조, 2군 병렬 그룹, 3상 RCT
Clinical phase 3 study to investigate the effect of recAP on 28 day mortality in patients admitted to the ICU with acute kidney injury that is caused by sepsis.
The study has three distinct SA-AKI trial populations:
- The main trial population: Patients with a pre-AKI reference eGFR ≥45 mL/min/1.73 m2 and no proven or suspected SARS-CoV-2 at time of randomization.
- A 'moderate' CKD population: Patients with a pre-AKI reference eGFR ≥25 and <45 mL/min/1.73 m2 and no proven or suspected SARS-CoV-2 at time of randomization.
- A Corona Virus Disease 2019 (COVID-19) population: Patients with proven or suspected SARS-CoV-2 at time of randomization with or without 'moderate' CKD. For patients in this population, COVID-19 should be the main cause of SA-AKI.
In the main study population approximately 1400 patients will be enrolled and in the two cohorts with moderate CKD and COVID-19 each up to 100 patients.
There are two arms in the study, one with active treatment and one with an inactive compound (placebo). Treatment is by 1 hour intravenous infusion, for three days. Patients are followed up for 28 days to see if there is an improvement on mortality, and followed for 90 and 180 days for mortality and other outcomes e.g. long-term kidney function and quality of life.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Sepsis is the leading cause of acute kidney injury (AKI) and a major cause of death. Patients with SA-AKI have a high mortality and morbidity and are at risk of developing chronic kidney disease. AP is a homodimeric endogenous enzyme present in many cells and organs, e.g., intestines, placenta, liver, bone, kidney, and granulocytes. It exerts detoxifying effects through dephosphorylation of endotoxins; pathogen associated molecular pattern molecules (PAMPS e.g., lipopolysaccharide) and damage-associated molecular pattern molecules (DAMPS e.g., adenosine tri- and di-phosphate). In animal models of sepsis and AKI, administration of AP attenuates the inflammatory response, improves renal function and/or reduces mortality.
AM-Pharma B.V. is developing AP as a novel, recombinant chimeric human AP medicinal product, called recAP, to be used as an intravenous infusion for the treatment of SA-AKI. In the Phase 2 trial STOP-AKI, a survival benefit was observed in the two highest dose groups, 0.8 mg/kg and 1.6 mg/kg groups, compared to the placebo group. There were no safety or tolerability concerns for any of the doses tested (0.4, 0.8 and 1.6 mg/kg). The 1.6 mg/kg recAP dose was selected for this Phase 3 trial based on the significant survival benefit observed. PK/PD simulations also confirmed this dose to have the most pronounced treatment effect.
The primary objective of this Phase 3 trial is to confirm the mortality benefit seen in STOP-AKI by demonstrating a reduction in 28 day all cause mortality in patients with SA-AKI treated with 1.6 mg/kg recAP.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Amsterdam, 네덜란드, 1081 HV
- Amsterdam UMC - VUMC
-
Ede, 네덜란드, 6716 RP
- Ziekenhuis Gelderse Vallei
-
Enschede, 네덜란드, KZ 7512
- Medisch Spectrum Twente
-
Heerlen, 네덜란드, Heerlen
- Zuyderland Medisch Centrum, Heerlen
-
Nijmegen, 네덜란드, 6532 SZ
- Canisius-Wilhelmina Ziekenhuis
-
Nijmegen, 네덜란드, 6500 HB
- Radboud UMC
-
-
North Brabant
-
's-Hertogenbosch, North Brabant, 네덜란드, 5223 GZ
- Jeroen Bosch Ziekenhuis lokatie GZG
-
-
-
-
-
Auckland, 뉴질랜드, 1023
- Auckland City Hospital
-
Auckland, 뉴질랜드, 2025
- Middlemore Clinical Trials
-
Christchurch, 뉴질랜드, 8140
- Christchurch Hospital
-
Dunedin, 뉴질랜드, 9016
- Dunedin Hospital
-
Grafton, 뉴질랜드, 1023
- Auckland City Hospital
-
Hastings, 뉴질랜드, 4172
- Hawke's Bay Hospital Soldiers' Memorial
-
Rotorua, 뉴질랜드, 3046
- Lakes District Health Board - Rotorua Hospital
-
-
WGN
-
Wellington, WGN, 뉴질랜드, 6021
- Wellington Hospital
-
-
-
-
-
Aalborg, 덴마크, 9000
- Aalborg Universitetshospital
-
Aarhus N, 덴마크, 8200
- Aarhus University Hospital
-
Copenhagen, 덴마크, 2100
- Rigshospitalet
-
Herning, 덴마크, 7400
- Herning Regional Hospital
-
Hillerød, 덴마크, 3400
- Nordsjællands Hospital
-
Køge, 덴마크, 4600
- Sjaellands Universitetshospital, Koge - Kardiologisk Afdeling
-
Odense C, 덴마크, 5000
- Odense Universitetshospital
-
Randers, 덴마크, 8930
- Regionshospitalet Randers
-
Slagelse, 덴마크, 4200
- Slagelse Sygehus
-
Viborg, 덴마크, 8800
- Hospitalsenhed Midt
-
-
-
-
-
Aachen, 독일, 52074
- Universitätsklinikum Aachen
-
Hamburg, 독일, 20246
- Universitätsklinikum Hamburg-Eppendorf (UKE)
-
Jena, 독일, 7747
- University Hospital Jena - Klinik fur Neurologie
-
Leipzig, 독일, 4103
- Universitaetsklinikum Leipzig - Klinik und Poliklinik fuer Gastroenterologie und Rheumatologie
-
Münster, 독일, 48149
- University Hospital Münster
-
-
-
-
Arizona
-
Tucson, Arizona, 미국, 85724-5057
- The University of Arizona Cancer Center
-
-
California
-
Los Angeles, California, 미국, 90095-8358
- Ronald Reagan UCLA Medical Center
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20037-2342
- The George Washington University Medical Faculty Associates - Anesthesiology
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322-1007
- Emory Clinical Cardiovascular Research Institute
-
-
Illinois
-
Glenview, Illinois, 미국, 60026-1301
- Glenbrook Hospital
-
Highland Park, Illinois, 미국, 60035
- NorthShore Medical Group - Bannockburn
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40508-3215
- University of Kentucky College of Medicine (UKCM)
-
-
Minnesota
-
Saint Paul, Minnesota, 미국, 55101
- Regions Hospital
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87131
- University of New Mexico School of Medicine
-
-
North Carolina
-
Winston-Salem, North Carolina, 미국, 27157
- Wake Forest Baptist Medical Center
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45219
- University of Cincinnati Cancer Institute
-
Columbus, Ohio, 미국, 43210
- The Ohio State University - Dorothy M. Davis Heart and Lung Research Institute
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15213-3108
- UPMC CancerCenter at Magee - Womens Hospital
-
Pittsburgh, Pennsylvania, 미국, 15213-3108
- UPMC Presbyterian
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22908-0817
- University of Virginia Health System
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국, 53226-3522
- Froedtert & the Medical College of Wisconsin Froedtert Hospital
-
-
-
-
-
Brussels, 벨기에, 1020
- Centre Hospitalier Universitaire Brugmann
-
Charleroi, 벨기에, 6042
- Centre Hospitalier Universitaire (CHU) de Charleroi - Hopital Civil Marie Curie
-
Genk, 벨기에, 3600
- Ziekenhuis Oost-Limburg
-
Ghent, 벨기에, 9000
- Universitair Ziekenhuis Gent
-
Jette, 벨기에, 1090
- Universitair Ziekenhuis Brussel
-
La Louvière, 벨기에, 7100
- Hôpital de JOLIMONT
-
Ottignies, 벨기에, 1340
- Clinique Saint-Pierre- Ottignies
-
Woluwe-Saint-Lambert, 벨기에, 1200
- Cliniques Universitaires Saint-Luc
-
Yvoir, 벨기에, 5530
- CHU UCL Namur - Mont-Godinne
-
-
-
-
-
Badalona, 스페인, 8916
- Hospital Universitari Germans Trias i Pujol
-
Barcelona, 스페인, 8035
- Hospital Universitario Vall d'Hebron
-
Barcelona, 스페인, 8907
- Hospital Universitari de Bellvitge (IDIBELL)
-
Barcelona, 스페인, 8003
- Hospital del Mar
-
Girona, 스페인, 17007
- Hospital Universitari de Girona Doctor Josep Trueta
-
Madrid, 스페인, 28040
- Hospital Clínico San Carlos
-
Sabadell, 스페인, 8208
- Parc Taulí Sabadell Hospital Universitari
-
Terrassa, 스페인, 8221
- Universitat de Barcelona - Hospital Universitari Mutua Terrassa (HUMT)
-
-
-
-
-
Dublin, 아일랜드, D08 NHY1
- St. James's Hospital
-
Dublin, 아일랜드, D24NR0A
- Tallaght University Hospital
-
Dublin, 아일랜드, Dublin 4
- St. Vincent's University Hospital
-
-
G
-
Galway, G, 아일랜드, H91 YR71
- National University of Ireland, Galway
-
-
-
-
-
Cardiff, 영국, CF14 4XW
- University Hospital of Wales
-
Liverpool, 영국, L7 8XP
- Royal Liverpool University Hospital
-
London, 영국, SE1 7EH
- Guy's and St Thomas' NHS Foundation Trust - St Thomas' Hospital
-
Plymouth, 영국, PL6 8DH
- Plymouth Hospitals NHS Trust - Derriford Hospital
-
-
LND
-
London, LND, 영국, NW1 2BU
- University College London Hospitals NHS Foundation Trust - University College Hospital
-
-
-
-
-
Graz, 오스트리아, 8036
- Medizinische Universitaet Graz - Klinik fuer Innere Medizin
-
Innsbruck, 오스트리아, 6020
- Medizinische Universität Innsbruck
-
Innsbruck, 오스트리아, 6020
- Medizinische Universitaet Innsbruck - Universitaetsklinik fuer Innere Medizin I
-
-
-
-
-
Hachioji-Shi, 일본, 193-0998
- Tokyo Medical University Hachioji Medical Center
-
Hiroshima, 일본
- Hiroshima University Hospital
-
Izuka-shi, 일본, 820-8505
- Aso Iizuka Hospital
-
Izumisano, 일본, 598-8577
- Rinku General Medical Center
-
Kashihara-shi, 일본, 634-8522
- Nara Medical University Hospital
-
Kumamoto, 일본, 860-0008
- National Hospital Organization Kumamoto Medical Center
-
Osaka, 일본, 534-0021
- Osaka City General Hospital
-
Osaka, 일본, 543-0035
- Osaka Police Hospital
-
Toyoake-Shi, 일본, 470-1192
- Fujita Health University Hospital
-
Yokohama, 일본, 245-8575
- National Hospital Organization - Yokohama Medical Center
-
Ōmihachiman, 일본, 523-0082
- Omihachiman Community Medical Center
-
-
-
-
-
Calgary, 캐나다, T1Y 6J4
- Peter Lougheed Centre
-
Calgary, 캐나다, T2N 2T9
- Foothills Medical Centre
-
Calgary, 캐나다, T2V 1P9
- Rockyview General Hospital
-
Calgary, 캐나다, T3M 1M4
- Alberta Health Services - South Health Campus Hospital
-
Ottawa, 캐나다, K1H 8L6
- The Ottawa Hospital - General Campus
-
Ottawa, 캐나다, K1Y 4E9
- The Ottawa Hospital - Civic Campus
-
Québec, 캐나다, G1J 1Z4
- Hôpital de l'Enfant-Jésus
-
Vancouver, 캐나다, V6Z 1Y6
- St. Paul's Hospital
-
Victoria, 캐나다, V8R 1J8
- Royal Jubilee Hospital (RJH)
-
Victoria, 캐나다, V8R 1J8
- Victoria General Hospital (VGH)
-
-
-
-
-
Angers, 프랑스, 49933
- Centre Hospitalier Universitaire d'Angers
-
Argenteuil, 프랑스, 95107
- Centre Hospitalier d'Argenteuil
-
Béthune, 프랑스, 62408
- Centre Hospitalier de Bethune Germon et Gauthier
-
Cergy-Pontoise, 프랑스, 95303
- Centre Hospitalier René-Dubos
-
Dijon, 프랑스, 21079
- CHU Dijon - Hôpital François Mitterrand
-
La Roche-sur-Yon, 프랑스, 85000
- Centre Hospitalier Départemental de Vendée - Les Oudairies
-
Le Kremlin-Bicêtre, 프랑스, 94270
- Hôpital Bicêtre
-
Le Mans, 프랑스, 72000
- Centre Hospitalier du Mans
-
Limoges, 프랑스, 87000
- CHU Limoges - Hôpital Dupuytren
-
Nancy, 프랑스, 54000
- CHU de Nancy
-
Nantes, 프랑스, 44000
- CHU de Nantes - Hôtel-Dieu
-
Nîmes, 프랑스, 30029
- CHU de Nimes - Hopital Universitaire Caremeau
-
Orléans, 프랑스, 45067
- Hôpital La Source
-
Paris, 프랑스, 75010
- Hôpital Lariboisière
-
Strasbourg, 프랑스, 67091
- Hôpitaux Universitaires de Strasbourg - Hôpital Civil
-
Tours, 프랑스, 37044
- CHRU de Tours - Hôpital Bretonneau
-
-
-
-
-
Helsinki, 핀란드, 290
- Helsinki University Central Hospital (HUCH)
-
Tampere, 핀란드, 33521
- Tampere University Hospital
-
Turku, 핀란드, 20521
- Turku University Hospital (TYKS)
-
-
-
-
-
Bedford Park, 호주, 5042
- Flinders Medical Centre
-
Bendigo, 호주, 3550
- Bendigo Hospital
-
Footscray, 호주, 3011
- Footscray Hospital
-
Melbourne, 호주, 3084
- Austin Hospital
-
New Lambton Heights, 호주, 2305
- John Hunter Hospital
-
Saint Albans, 호주, 3021
- Sunshine Hospital ICU - Western Hospital
-
Southport, 호주, 4215
- Gold Coast University Hospital (GCUH)
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
18 years or older.
-
In the ICU or intermediate care unit for clinical reasons.
-
Have sepsis requiring vasopressor (norepinephrine, epinephrine, dopamine, phenylephrine, vasopressin, or angiotensin II) therapy, i.e.:
- suspected or proven bacterial or viral infection. and
- on vasopressor therapy (≥0.1 µg/kg/min norepinephrine or equivalent) for sepsis-induced hypotension for at least one hour despite adequate fluid resuscitation according to clinical judgement. Following the initial one hour on at least 0.1 µg/kg/min norepinephrine or equivalent, any dose of vasopressor counts as vasopressor therapy.
The combination of a) and b) automatically ensures that patients fulfill the Sepsis 3 criteria as 0.1 µg/kg/min norepinephrine corresponds to a score of +4 on the Cardiovascular sub-score of the SOFA score.
-
Have AKI according to at least one of the below KDIGO criteria, a to d:
-
An absolute increase in serum or plasma creatinine (CR) by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 hours.
or
-
A relative increase in CR to ≥1.5 times the pre-AKI reference CR value which is known or presumed to have occurred within prior 7 days.
or
-
A decrease in urinary output to <0.5 mL/kg/hour for a minimum of 6 hours following adequate fluid resuscitation.
or d) If the patient does not have a known history of CKD and there is no pre-AKI reference CR value available from the past 12 months available from the past 12 months: a CR value greater or equal to the levels presented in Table 1, with the increase in CR presumed to have occurred within prior 7 days.
-
-
Provision of signed and dated ICF in accordance with local regulations.
Exclusion Criteria:
-
a) At sites where enrolment of 'moderate' CKD patients is allowed, patients with 'severe' CKD defined as a pre-AKI reference eGFR <25 mL/min/1.73 m2 are excluded.
-
For patients with known CKD, the most recent eGFR prior to index hospitalization needs to be documented as ≥25 mL/min/1.73 m2.
-
For patients with known CKD but no known eGFR prior to hospitalization, presentation eGFR between 25-60 mL/min/1.73 m2 can also be used to rule out 'severe' CKD.
b) At sites where enrolment of 'moderate' CKD patients is NOT allowed, patients with 'moderate' and 'severe' CKD defined as a pre-AKI reference eGFR <45 mL/min/1.73 m2 are excluded.
-
For patients with known CKD, the most recent eGFR prior to index hospitalization needs to be documented as ≥45 mL/min/1.73 m2.
-
For patients with known CKD but no known eGFR prior to hospitalization, presentation eGFR between 45-60 mL/min/1.73 m2 can also be used to rule out 'moderate' and 'severe' CKD.
-
-
Advanced chronic liver disease, defined as a Child-Pugh score of 10 to 15 (Class C).
-
Acute pancreatitis without proven infection.
-
Urosepsis related to suspected or proven urinary tract obstruction.
-
Main cause of AKI not sepsis.
-
Proven or suspected SARS-CoV-2 infection. NOTE: This exclusion criterion does not apply to patients in the COVID-19 population, in which COVID-19 should be the main cause of SA-AKI.
-
Severe burns requiring ICU treatment.
-
Severely immunosuppressed, e.g. due to:
- hematopoietic cell transplantation within past 6 months prior to Screening or acute or chronic graft-versus-host disease
- solid organ transplantation
- leukopenia not related to sepsis, i.e., preceding sepsis
- Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)
- receiving chemotherapy within 30 days prior to Screening.
-
At high risk of being LTFU, e.g., due to known current or recent (within the last 6 months) IV drug abuse or known to be homeless.
-
Limitations to use of mechanical ventilation (MV), RRT or vasopressors and inotropes (NOTE: limitation of cardiopulmonary resuscitation (CPR) only is not an exclusion criterion).
-
Previous administration of recAP.
-
Use of a non-marketed drug within the last month or concurrent or planned participation in a clinical trial for a non-marketed drug or device. (NOTE: Co-enrollment or concurrent participation in observational, non-interventional trials using no protocolized treatments or procedures are always allowed. Co-enrollment or concurrent participation in trials using protocolized treatments or procedures, e.g. blood draws, requires pre-approval by the TSC).
-
Current or planned extracorporeal membrane oxygenation (ECMO).
-
On RRT >24 hours before start of trial drug.
-
No longer on vasopressor therapy at time of randomization.
-
On continuous vasopressor therapy for >72 hours before start of trial drug.
-
Estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m2 based on the most recent available CR sample at time of screening (NOTE: will often be the sample used to diagnose AKI). eGFR should be calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. In Japan, the CKD-EPI formula with Japanese coefficient should be used. If local regulations prohibit correcting for race in the calculation of eGFR, it is acceptable to use the formula without correcting for race.
-
Not feasible to start trial drug within:
-
48 hours from AKI diagnosis, when AKI diagnosis precedes start of vasopressor therapy.
or
-
24 hours from AKI diagnosis, when AKI is diagnosed after start of vasopressor therapy.
-
-
Pregnant or nursing women.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
위약 비교기: placebo
matching placebo |
Placebo |
|
실험적: active
recombinant human alkaline phosphatase 1.6mg/kg 3 daily 1 hour infusions |
patients with SA-AKI are randomly assigned in a 1:1 ratio to either placebo or 1.6 mg/kg recAP.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
28-day All-cause Mortality: Main Trial Population
기간: 28 days
|
To demonstrate an effect of recAP on 28 day all cause mortality |
28 days
|
|
28-day All-cause Mortality: Moderate Chronic Kidney Disease Population
기간: 28 days
|
To demonstrate an effect of recAP on 28 day all cause mortality |
28 days
|
|
28-day All-cause Mortality: COVID-19 Population
기간: 28 days
|
To demonstrate an effect of recAP on 28 day all cause mortality |
28 days
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Major Adverse Kidney Events 90: Main Trial Population
기간: 90 Days
|
Major adverse kidney events (MAKE) 90: dead by Day 90 or on Renal Replacement Therapy (RRT) at Day 90 or greater than or equal to 25% decline in estimated glomerular filtration rate (eGFR) on both Day 28 and Day 90 relative to the known or assumed pre-acute kidney injury reference level. |
90 Days
|
|
Major Adverse Kidney Events 90: Moderate Chronic Kidney Disease Population
기간: 90 Days
|
Major adverse kidney events (MAKE) 90: dead by Day 90 or on Renal Replacement Therapy (RRT) at Day 90 or greater than or equal to 25% decline in estimated glomerular filtration rate (eGFR) on both Day 28 and Day 90 relative to the known or assumed pre-acute kidney injury reference level. |
90 Days
|
|
Major Adverse Kidney Events 90: COVID-19 Population
기간: 90 Days
|
Major adverse kidney events (MAKE) 90: dead by Day 90 or on Renal Replacement Therapy (RRT) at Day 90 or greater than or equal to 25% decline in estimated glomerular filtration rate (eGFR) on both Day 28 and Day 90 relative to the known or assumed pre-acute kidney injury reference level. |
90 Days
|
|
Major Adverse Kidney Events Through Day 90: Combined Population
기간: 90 Days
|
Major Adverse Kidney Events through day 90 (MAKE90A) :
|
90 Days
|
|
Days Alive and Free of Organ Support Through Day 28: Main Trial Population
기간: 28 days
|
Days alive and free of organ support through Day 28, ie, days alive with no mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors, or inotropes (with death within 28 days counting as zero days) |
28 days
|
|
Days Alive and Free of Organ Support Through Day 28: Moderate Chronic Kidney Disease Population
기간: 28 days
|
Days alive and free of organ support through Day 28, ie, days alive with no mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors, or inotropes (with death within 28 days counting as zero days) |
28 days
|
|
Days Alive and Free of Organ Support Through Day 28: COVID-19 Population
기간: 28 days
|
Days alive and free of organ support through Day 28, ie, days alive with no mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors, or inotropes (with death within 28 days counting as zero days) |
28 days
|
|
Days Alive and Out of the ICU Through Day 28: Main Trial Population
기간: 28 days
|
Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days). |
28 days
|
|
Days Alive and Out of the ICU Through Day 28: Moderate Chronic Kidney Disease Population
기간: 28 days
|
Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days). |
28 days
|
|
Days Alive and Out of the ICU Through Day 28: COVID-19 Population
기간: 28 days
|
Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days). |
28 days
|
|
90-day All Cause Mortality: Main Trial Population
기간: 90 days
|
90-Day all-cause mortality |
90 days
|
|
90-day All Cause Mortality: Moderate Chronic Kidney Disease Population
기간: 90 days
|
90-Day all-cause mortality |
90 days
|
|
90-day All Cause Mortality: COVID-19 Population
기간: 90 days
|
90-Day all-cause mortality |
90 days
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: A Legters, AM-Pharma
간행물 및 유용한 링크
일반 간행물
- Pickkers P, Angus DC, Arend J, Bellomo R, van den Berg E, Bernholz J, Bestle M, Broglio K, Carlsen J, Doig CJ, Ferrer R, Joannidis M, Francois B, Doi K, Kellum JA, Laterre PF, Liu K, Mehta RL, Murray PT, Ostermann M, Pettila V, Richards S, Young P, Zarbock A, Kjolbye AL. Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injury. BMJ Open. 2023 Apr 3;13(4):e065613. doi: 10.1136/bmjopen-2022-065613.
- Pickkers P, Angus DC, Bass K, Bellomo R, van den Berg E, Bernholz J, Bestle MH, Doi K, Doig CJ, Ferrer R, Francois B, Gammelager H, Pedersen UG, Hoste E, Iversen S, Joannidis M, Kellum JA, Liu K, Meersch M, Mehta R, Millington S, Murray PT, Nichol A, Ostermann M, Pettila V, Solling C, Winkel M, Young PJ, Zarbock A; REVIVAL investigators. Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL). Intensive Care Med. 2024 Jan;50(1):68-78. doi: 10.1007/s00134-023-07271-w. Epub 2024 Jan 3.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- AP-recAP-AKI-03-01
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .